Year: 2023
Type: article
Study design: Observational Study
Abstract: BACKGROUND: Epidemiological studies that examined the association between Parkinson's disease (PD) and cancers led to inconsistent results, but they face a number of methodological difficulties. OBJECTIVE: We used results from genome-wide association studies (GWASs) to study the genetic correlation between PD and different cancers to identify common genetic risk factors. METHODS: We used individual data for participants of European ancestry from the Courage-PD (Comprehensive Unbiased Risk Factor Assessment for Genetics and Environment in Parkinson's Disease; PD, N = 16,519) and EPITHYR (differentiated thyroid cancer, N = 3527) consortia and summary statistics of GWASs from iPDGC (International Parkinson Disease Genomics Consortium; PD, N = 482,730), Melanoma Meta-Analysis Consortium (MMAC), Breast Cancer Association Consortium (breast cancer), the Prostate Cancer Association Group to Investigate Cancer Associated Alterations in the Genome (prostate cancer), International Lung Cancer Consortium (lung cancer), and Ovarian Cancer Association Consortium (ovarian cancer) (N comprised between 36,017 and 228,951 for cancer GWASs). We estimated the genetic correlation between PD and cancers using linkage disequilibrium score regression. We studied the association between PD and polymorphisms associated with cancers, and vice versa, using cross-phenotypes polygenic risk score (PRS) analyses. RESULTS: = 0.11 [0.03; 0.19]). There was a significant inverse association between the PRS for ovarian cancer and PD (odds ratio [OR] = 0.89 [0.84; 0.94]). Conversely, the PRS of PD was positively associated with breast cancer (OR = 1.08 [1.06; 1.10]) and inversely associated with ovarian cancer (OR = 0.95 [0.91; 0.99]). The association between PD and ovarian cancer was mostly driven by rs183211 located in an intron of the NSF gene (17q21.31). CONCLUSIONS: We show evidence in favor of a contribution of pleiotropic genes to the association between PD and specific cancers. © 2023 The Authors. Movement Disorders published by Wiley Periodicals LLC on behalf of International Parkinson and Movement Disorder Society. This article has been contributed to by U.S. Government employees and their work is in the public domain in the USA.
Source: Movement Disorders
DOI: 10.1002/mds.29337
Authors: Pierre‐Emmanuel Sugier, Elise A. Lucotte, Cloé Domenighetti, Matthew H. Law, Mark M. Iles, Kevin Brown, Christopher Amos, James D. McKay, Rayjean J. Hung, Mojgan Karimi, Delphine Bacq‐Daian, Anne Boland‐Augé, Robert Olaso, Jean‐françois Deleuze, Fabienne Lesueur, Evgenia Ostroumova, Ausrele Kesminiene, Florent de Vathaire, Pascal Guénel, Ashwin Ashok Kumar Sreelatha, Claudia Schulte, Sandeep Grover, Patrick May, Dheeraj R. Bobbili, Milena Radivojkov‐Blagojevic, Peter Lichtner, Andrew B. Singleton, Dena G. Hernandez, Connor Edsall, George D. Mellick, Alexander Zimprich, Walter Pirker, Ekaterina Rogaeva, Anthony E. Lang, Sulev Koks, Pille Taba, Suzanne Lesage, Alexis Brice, Jean‐Christophe Corvol, Marie‐Christine Chartier‐Harlin, Eugénie Mutez, Kathrin Brockmann, Angela B. Deutschländer, Georges M. Hadjigeorgiou, Efthimios Dardiotis, Leonidas Stefanis, Athina Maria Simitsi, Enza Maria Valente, Simona Petrucci, Letizia Straniero, Anna Zecchinelli, Gianni Pezzoli, Laura Brighina, Carlo Ferrarese, Grazia Annesi, Andrea Quattrone, Monica Gagliardi, Hirotaka Matsuo, Akiyoshi Nakayama, Nobutaka Hattori, Kenya Nishioka, Sun Ju Chung, Yun Joong Kim, Pierre Kolber, Bart P.C. van de Warrenburg, Bastiaan R. Bloem, Jan Aasly, Mathias Toft, Lasse Pihlstrøm, Leonor Correia Guedes, Joaquim J. Ferreira, Soraya Bardien, Jonathan Carr, Eduardo Tolosa, Mario Ezquerra, Pau Pastor, Monica Diez‐Fairen, Karin Wirdefeldt, Nancy Pedersen, Caroline Ran, Andrea C. Belin, Andreas Puschmann, Emil Ygland Rödström, Carl E. Clarke, Karen E. Morrison, Manuela Tan, Dimitri Krainc, Lena F. Burbulla, Matt J. Farrer, Rejko Kruger, Thomas Gasser, Manu Sharma, Thérèse Truong, Alexis Elbaz
Institutions: Centre National de la Recherche Scientifique, Université de Pau et des Pays de l'Adour, Inserm, Université de Versailles Saint-Quentin-en-Yvelines, Université Paris-Saclay, Laboratoire de Mathématiques et de leurs Applications, Centre de recherche en Epidémiologie et Santé des Populations, Queensland University of Technology, QIMR Berghofer Medical Research Institute, University of Leeds, National Institutes of Health, National Cancer Institute, Division of Cancer Epidemiology and Genetics, Baylor College of Medicine, Centre international de recherche sur le cancer, University of Toronto, Lunenfeld-Tanenbaum Research Institute, Sinai Health System, Commissariat à l'Énergie Atomique et aux Énergies Alternatives, Centre National de Recherche en Génomique Humaine, CEA Paris-Saclay, Institut de biologie François Jacob, Université Paris Sciences et Lettres, École Nationale Supérieure des Mines de Paris, Institut Curie, University of Tübingen, German Center for Neurodegenerative Diseases, Hertie Institute for Clinical Brain Research, University of Luxembourg, Luxembourg Centre for Systems Biomedicine, Helmholtz Munich, Institut für Humangenetik, National Institute on Aging, Griffith University, Medical University of Vienna, University Health Network, Toronto Western Hospital, Krembil Brain Institute, Murdoch University, Perron Institute for Neurological and Translational Science, Tartu University Hospital, University of Tartu, Sorbonne Université, Assistance Publique – Hôpitaux de Paris, Institut du Cerveau, Université de Lille, Centre Hospitalier Universitaire de Lille, Lille Neurosciences & Cognition, Max Planck Institute of Psychiatry, Ludwig-Maximilians-Universität München, University of Thessaly, University of Cyprus, University Hospital of Larissa, Mayo Clinic in Florida, National and Kapodistrian University of Athens, Biomedical Research Foundation of the Academy of Athens, Eginition Hospital, University of Pavia, Istituti di Ricovero e Cura a Carattere Scientifico, Azienda Ospedaliera Sant'Andrea, Sapienza University of Rome, Humanitas University, Grigioni Foundation for Parkinson's disease, Azienda Ospedaliera San Gerardo, University of Milano-Bicocca, Institute for Biomedical Research and Innovation, National Research Council, Magna Graecia University, National Defense Medical College, Juntendo University, Asan Medical Center, University of Ulsan, Yonsei University, Yonsei University Health System, Centre Hospitalier de Luxembourg, Radboud University Nijmegen, Radboud University Medical Center, Donders Institute for Brain, Cognition and Behaviour, Norwegian University of Science and Technology, St Olav's University Hospital, Oslo University Hospital, University of Lisbon, Centro Hospitalar Lisboa Norte, Hospital de Santa Maria, Instituto de Medicina Molecular João Lobo Antunes, Stellenbosch University, Instituto de Salud Carlos III, Biomedical Research Networking Center on Neurodegenerative Diseases, Hospital Clínic de Barcelona, Consorci Institut D'Investigacions Biomediques August Pi I Sunyer, Universitat de Barcelona, Hospital Universitari Germans Trias i Pujol, University Hospital Mútua de Terrassa, Mútua Terrassa, Karolinska Institutet, Lund University, Skåne University Hospital, Sandwell & West Birmingham Hospitals NHS Trust, University of Birmingham, Queen's University Belfast, Northwestern University, Munich Cluster for Systems Neurology, University of Florida, Luxembourg Institute of Health
Language: English
Subfield: Genetics
Domain: Life Sciences
Open Access status: hybrid
Estimated APC paid: $4,070
Funders: U.S. Department of Defense, Breast Cancer Research Foundation, Ovarian Cancer Research Fund, World Health Organization, National Institute on Handicapped Research, International Parkinson and Movement Disorder Society, National Cancer Research Institute, Centre International de Recherche sur le Cancer, Pancreatic Cancer UK, Wellcome Trust, Swedish Cancer Foundation, EU Joint Programme – Neurodegenerative Disease Research, CNIB, Government of Canada, Cancer Research UK, National Institute for Health and Care Research, European Commission, Rosetrees Trust, VicHealth, Institut National de la Santé et de la Recherche Médicale, Lunds Universitet, Ligue Contre le Cancer, Vetenskapsrådet, Skånes universitetssjukhus, National Institutes of Health, Parkinsonfonden, Seventh Framework Programme, Canadian Institutes of Health Research, Cancer Council Victoria, National Heart, Lung, and Blood Institute, National Human Genome Research Institute, National Cancer Institute, Institute of Cancer Research, Division of Arctic Sciences, Division of Cancer Epidemiology and Genetics, National Cancer Institute, FP7 Health
Awards: G1081030536, G108412983, G1127799983, G1148307873, G1161123863, A genome-wide association study for breast cancer in BRCA1 mutation carriers, G1278116854, G1295075329, G1332421352, G1364610698, G1508859565, G1516858932, G1584405745, G1587186860, G1589121050, G1795870773, G1797923650, G1811486015, G188264227, G1996730814, G2014201421, G2036036603, G2055294773, G2140730164, G2219507223, G2242167451, G2294118639, G2313227773, G234016028, G236237718, G2373099447, Breast CAncer STratification: understanding the determinants of risk and prognosis of molecular subtypes, G2445392763, G2453522775, G2454630106, G2503596831, G2620578876, G2691119185, G2694076841, G2718683818, G2730950932, G2734198957, G2785925516, G2786222541, G3188551179, G3226771441, G3248832364, G3276551827, G3295228044, G3387721620, G3430830446, G3503022892, G3587954126, G3602505857, G3607452959, Breast Cancer Risk after Diagnostic Gene Sequencing (BRIDGES), Elucidating Loci Involved in Prostate Cancer Suceptibility, G3773105699, G3794179797, G380538514, G3891343362, G395156118, G4043398722, G407478442, G4103474500, G4119534169, G4119975330, G4167275758, G4197410787, G430627353, G4333708648, G4345139362, G4407350458, G4530141046, G4690478475, Characterizing Genetic Susceptibility to Breast and Prostate Cancer; the BPC3, G4727172548, G4744540905, G475260568, G4849618962, G4915529853, G495186059, G4991908250, G5019474394, G5048543170, G5101912108, G5395379871, G5549244980, G5583696067, G5715271531, G5756664977, G5850682332, G586064783, G60573655, G621290712, G6228767644, G6229591247, G6366270716, G6376423330, G6379995370, G6433750405, G6453123296, G6480339625, G6838654718, G6862617662, G6945661269, G7006486244, G704544610, G711535872, G7242219286, G7243203649, G7280168628, G728243498, G734892404, G7356174861, G7356264847, G7410254275, G7510707455, G751661945, G7550424651, G7570543806, G7570682278, G7808646444, G7891086452, G790382466, G7973277461, G8209208257, G821701785, GENETIC MODIFIERS OF OVARIAN CANCER, G8344269847, Targeting the allosteric control of alarmone synthetases to tackle bacteria persistence, G8623054353, G8703060161, G880611044, G8818365897, G8834430567, G8853615787, G8854317076, G8959936493, G9000010279, G9000025899, G9000042844, G9000081378, G9000123888, G9000175716, G9000200580, G9000253373, G9000301350, G952755447
OpenAlex ID: W4320856410